Skip to main content

Table 5 HbA1c and body weight

From: Treatment satisfaction and quality-of-life between type 2 diabetes patients initiating long- vs. intermediate-acting basal insulin therapy in combination with oral hypoglycemic agents – a randomized, prospective, crossover, open clinical trial

  Baseline (Visit 2) ∆ from baseline ∆ from end of period 1 p-value*
HbA1c in %, mean ± SD     
Sequence A 8.17 ± 0.73 −1.17 ± 1.05 0.21 ± 0.58 <0.0001
Sequence B 8.13 ± 0.72 −1.17 ± 0.93 0.09 ± 0.63 <0.0001
p-value**   0.97 0.10  
Body weight in kg, mean ± SD     
Sequence A 90.1 ± 15.8 0.40 ± 3.31 0.67 ± 2.51 0.70
Sequence B 91.0 ± 15.13 0.51 ± 3.34 0.73 ± 3.10 0.68
p-value**   0.77 0.86  
  1. Legend: * Paired t-test was applied for comparison of treatments within sequence; ** Unpaired t-test was applied for comparison of treatments in periods; Sequence A: starting with insulin glargine and then switching to NPH insulin; Sequence B: starting with NPH insulin and then switching to insulin glargine